Tarapur Transformers Ltd. Share Price

NGL Fine-Chem Ltd Company Fundamental Analysis

NGL Fine-Chem is a pharmaceutical company specialising in active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations, with a strong focus on veterinary medicines and selected human-health products. Its portfolio includes 32 APIs for veterinary and human use, and the company exports to more than 51 countries. Its integrated manufacturing capabilities and regulatory approvals provide opportunities to benefit from growing global animal-health demand and the China+1 sourcing trend. The expansion of its Tarapur manufacturing facility is intended to support additional production capacity and future growth. FY26 consolidated revenue increased 36% to approximately ₹501 crore, while net profit rose 128% to ₹48.1 crore, indicating a significant improvement in profitability. Q1 FY27 revenue reached ₹139.2 crore, up 33.6% year-on-year, while operating profit increased 112% to ₹23.3 crore and net profit rose 99% to ₹18.4 crore. Operating profitability improved considerably, with the operating margin reaching approximately 16.7%. However, the recently commissioned capacity will need to achieve healthy utilisation and customer demand to sustain this growth. The company also faces a GST notice for an alleged short payment of approximately ₹6.18 crore, which requires monitoring until resolved. At the latest available Groww data, NGL Fine-Chem had a market capitalisation of approximately ₹1,709 crore, P/E of 29.9x, P/B of 5.19x, ROE of 14.6% and debt-to-equity of 0.33x. Growth drivers include veterinary healthcare demand, export expansion, new manufacturing capacity and a wider product portfolio. Overall, NGL Fine-Chem has demonstrated strong earnings momentum and international reach, but sustaining margins and generating adequate returns from its new capacity will be essential to support its valuation.

See More

Strong Q2 FY27 Results, Robust Order Bookuture

Transformers & Rectifiers (India) Ltd. (TARIL): Strong Q2 FY27 Results, Robust Order Book and Future Growth Potential By Neha Gupta | SEBI Registered Research Analyst

SEBI Registration No.: INH000016542 Transformers & Rectifiers (India) Ltd. (TARIL) is an established player in India's electrical equipment and transformer manufacturing industry. The company manufactures power transformers, furnace transformers, rectifier transformers, distribution transformers, reactors and other specialised electrical equipment for power generation, transmission, distribution and industrial applications. With India's growing electricity demand, expansion of transmission infrastructure and increasing investments in power systems, transformer manufacturers have an important role to play in supporting the country's energy infrastructure. Against this backdrop, TARIL's Q2 FY27 financial performance presents several important developments for investors to evaluate. Strong Q2 FY27 Financial Performance TARIL reported a significant improvement in its consolidated financial performance for the quarter ended September 2026 Conclusion Transformers & Rectifiers (India) Ltd. has delivered strong Q2 FY27 revenue and profit growth, supported by improved operating performance and healthy order inflows. Its business operates in an industry linked to India's power infrastructure requirements, which may provide opportunities for further growth. Disclaimer: This article is intended solely for educational and informational purposes and does not constitute investment advice, a recommendation to buy or sell any security, or an assurance of returns. The information should be independently verified before being relied upon. Investors should consider their financial objectives, risk tolerance and independent research before making investment decisions.

See More

BHAGERIA INDUSTRIES FUNDAMENTAL RESEARCH REPORT

Bhageria Industries (NSE: BHAGERIA, BSE: 530803), Mumbai, makes dye intermediates - H-acid (its largest product, 30-35% ofrevenue), vinyl sulphone, gamma acid, J-acid and Tobias acid - at Vapi (Gujarat) and Tarapur (Maharashtra), with its own 300t/day sulphuric-acid plant for backward integration. It also owns ~34 MW of operating solar plants on 25-year power-purchase agreements (Rs 27-30 Cr of revenue a year), a small pharmaceutical subsidiary, and has started making ***** 35% of revenue is exported; customers include Everlight Chemical and Huntsman. Promoted by the Bhageria familysince 1989. Rated CARE A/Stable (8-Oct-2026). Event 1 - volume came back, then price followed. FY26 consolidated revenue rose 47% to Rs 874 Cr on volume, but themargin fell to ~10.6% (CARE) on raw-material swings, logistics and competition; PAT was Rs 44 Cr. In Q1 FY27 revenue jumped 82% to Rs 286 Cr as product prices rose steeply, and PAT reached Rs 34 Cr (+203%) . Chemicals segment profi t was Rs 37.5 Cragainst Rs 15.1 Cr a year earlier. Part of the quarter’s profi t was Rs 16.6 Cr of other income (36% of PBT; it was negative in Q4),which we treat as non-core.

See More

Bhageria Industries Ltd Company Analysis

Bhageria Industries is a diversified business with its core operations in specialty chemicals, particularly dye and pigment intermediates, alongside solar power generation and a developing pharmaceutical business. The chemicals segment is currently the main earnings driver, supported by expanded H-Acid capacity from 400 to 500 tonnes per month and the commencement of plasticizer production at Tarapur. FY26 showed a substantial improvement, with consolidated revenue from operations reaching about ₹874 crore versus ₹597 crore in FY25. Chemical-segment revenue increased to about ₹830 crore from ₹504 crore, while the solar segment remained relatively stable at ₹26.9 crore. Q1 FY27 continued this momentum, with consolidated revenue of ₹286.4 crore, up 81.9% YoY, and PAT of ₹33.9 crore, up 210.7%. EBITDA increased to ₹57.6 crore, with operating margin improving sharply to 20.1% from 15.4% in Q1 FY26. The major growth opportunity lies in scaling H-Acid and plasticizer capacity, improving export volumes and expanding the solar portfolio. The company commissioned additional solar capacity during FY26 and added another 7 MW in May 2026, taking installed solar capacity to 21 MW. At around ₹352 as of 24 September 2026, the stock was valued at approximately ₹1,528 crore market capitalisation, with P/E around 22.6x, ROE 7.7% and debt-to-equity around 0.17x. Key risks include specialty-chemical cyclicality, raw-material and export-market volatility, relatively modest return ratios, working-capital requirements and execution risk in new capacity. The recent earnings acceleration is significant, but sustaining margins and converting capacity expansion into consistent cash generation will be important to monitor.

See More

Aarti Drugs: Moving up the pharma value chain

# Aarti Drugs: Moving up the pharma value chain Aarti Drugs Limited is moving beyond its traditional API business through backward integration, formulations and CDMO opportunities. The company plans ₹150–200 crore of annual capex for the next two years. The key focus is metformin. Aarti Drugs has already increased capacity to around 1,450–1,500 tonnes per month and plans to take this to 1,800–1,900 tonnes. It is also pursuing US FDA approval and plans to forward-integrate into metformin formulations. The company is also exploring CDMO opportunities in chlorosulfonation chemistry, where it already has manufacturing expertise, while expanding cardiovascular and antifungal products. This matters because APIs are more exposed to pricing cycles. Moving further downstream into regulated formulations and specialised manufacturing can potentially improve realisations and margins. Aarti Drugs has already completed around ₹600 crore of capex across Sayakha and Tarapur, while management estimates more than ₹1,200 crore of revenue potential from completed projects. **My view:** The interesting part of Aarti Drugs is the transition from an API-led business toward a more integrated pharma platform. The key test is whether the new capacity gets utilised fast enough to generate attractive returns on the capital invested. **What I'm watching:** Sayakha utilisation, metformin forward integration, regulated-market approvals, CDMO wins and return on capital. **Stance:** Capacity creation is only the first step. Execution and utilisation will determine whether the investment cycle translates into sustainable earnings growth. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

See More

Vipul Organics Starts Production at Sayakha Greenfield Plant; Consolidates Pigment Ops

Vipul Organics has commenced production at its new greenfield manufacturing facility in Sayakha, Gujarat. The company has also consolidated its pigment production from the Tarapur unit at the new Sayakha plant. This expansion significantly boosts capacity and is expected to improve operational efficiencies and cost competitiveness in the pigments segment. The facility supports the company’s growth plans in specialty chemicals and high-performance pigments. Top stocks in the dyes & pigments industry: Sudarshan Chemical Industries,

, and Bodal Chemicals.

See More